Treadwell Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Treadwell Therapeutics General Information
Description
Developer of a biotechnology platform designed to exploit cancer cell vulnerabilities and provide small molecules to address unmet needs in patients. The company's platform helps discover and develop a multifunctional engine that requires highly experienced experts in both drug discovery and early to late-stage clinical development, enabling patients to recover faster from various diseases.
Contact Information
Website
www.treadwelltx.comCorporate Office
- Unit 506, 5/F New World Tower 1
- 18 Queens Road Central
- Hong Kong
- Hong Kong
Corporate Office
- Unit 506, 5/F New World Tower 1
- 18 Queens Road Central
- Hong Kong
- Hong Kong
Treadwell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 2. Early Stage VC (Series B) | 18-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Seed Round | 13-Jan-2020 | $27M | $27M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Treadwell Therapeutics Patents
Treadwell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025088530-A1 | T cell receptors and methods of use thereof | Inactive | 24-Oct-2023 |
Treadwell Therapeutics Signals
Treadwell Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3W Partners Capital | PE/Buyout | Minority | ||
| China Fortune Ocean Fund | Venture Capital | Minority | ||
| Fuhai Assets | Asset Manager | Minority | ||
| Prosperous Alliance | Asset Manager | Minority | ||
| Sino Biopharmaceutical | Corporation | Minority |
Treadwell Therapeutics Acquisitions (1)
Treadwell Therapeutics’s most recent deal was a Merger/Acquisition with TCRyption. The deal was made on 15-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TCRyption | 15-Oct-2021 | Merger/Acquisition | Biotechnology |
Treadwell Therapeutics FAQs
-
When was Treadwell Therapeutics founded?
Treadwell Therapeutics was founded in 2018.
-
Where is Treadwell Therapeutics headquartered?
Treadwell Therapeutics is headquartered in Hong Kong, Hong Kong.
-
What is the size of Treadwell Therapeutics?
Treadwell Therapeutics has 14 total employees.
-
What industry is Treadwell Therapeutics in?
Treadwell Therapeutics’s primary industry is Drug Discovery.
-
Is Treadwell Therapeutics a private or public company?
Treadwell Therapeutics is a Private company.
-
What is Treadwell Therapeutics’s current revenue?
The current revenue for Treadwell Therapeutics is .
-
How much funding has Treadwell Therapeutics raised over time?
Treadwell Therapeutics has raised $118M.
-
Who are Treadwell Therapeutics’s investors?
3W Partners Capital, China Fortune Ocean Fund, Fuhai Assets, Prosperous Alliance, and Sino Biopharmaceutical are 5 of 7 investors who have invested in Treadwell Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process